Equities Analysts Issue Forecasts for IKT Q2 Earnings

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) – Research analysts at HC Wainwright boosted their Q2 2026 EPS estimates for Inhibikase Therapeutics in a report released on Tuesday, May 26th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.10) per share for the quarter, up from their prior forecast of ($0.11). The consensus estimate for Inhibikase Therapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Inhibikase Therapeutics’ Q3 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($0.42) EPS, Q1 2027 earnings at ($0.13) EPS, Q2 2027 earnings at ($0.13) EPS, Q3 2027 earnings at ($0.12) EPS, Q4 2027 earnings at ($0.11) EPS and FY2027 earnings at ($0.48) EPS.

Inhibikase Therapeutics (NASDAQ:IKT) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10).

A number of other equities research analysts also recently issued reports on IKT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research note on Tuesday, April 21st. LADENBURG THALM/SH SH assumed coverage on shares of Inhibikase Therapeutics in a research note on Wednesday, March 4th. They set a “buy” rating and a $4.00 price target on the stock. Finally, Lifesci Capital raised shares of Inhibikase Therapeutics to a “strong-buy” rating in a research note on Monday, February 23rd. Four research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $5.50.

Inhibikase Therapeutics Price Performance

Inhibikase Therapeutics stock opened at $1.70 on Thursday. The company has a market cap of $224.45 million, a price-to-earnings ratio of -3.95 and a beta of 0.96. The firm’s fifty day moving average is $1.78 and its 200 day moving average is $1.74. Inhibikase Therapeutics has a 52-week low of $1.33 and a 52-week high of $2.26.

Institutional Investors Weigh In On Inhibikase Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. The Manufacturers Life Insurance Company purchased a new stake in shares of Inhibikase Therapeutics in the first quarter valued at $48,000. SummitTX Capital L.P. purchased a new stake in shares of Inhibikase Therapeutics in the first quarter valued at $2,561,000. Kalehua Capital Management LLC raised its stake in shares of Inhibikase Therapeutics by 118.4% in the first quarter. Kalehua Capital Management LLC now owns 3,821,890 shares of the company’s stock valued at $6,421,000 after acquiring an additional 2,071,890 shares during the period. Rangeley Capital LLC purchased a new stake in shares of Inhibikase Therapeutics in the first quarter valued at $370,000. Finally, Renaissance Technologies LLC purchased a new stake in shares of Inhibikase Therapeutics in the first quarter valued at $28,000. Hedge funds and other institutional investors own 3.81% of the company’s stock.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.